In summary, this study will study the potential therapeutical effects of denosumab (RANKL inhibitior) on patients with sarcopenia and underlying osteoporosis, which will be crucial given the aging population and expected increase in disease numbers. Here, TNFSF11 is linked to osteoporosis.